
News|Videos|June 27, 2024
Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities
Multiple sclerosis (MS) specialists discuss their observations regarding variations in MS presentation and progression among patients of Different Races and Ethnicities
Advertisement
Episodes in this series

Do you see mild MS in patients of Different Races and Ethnicities
Advertisement
Related to this article

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Gefurulimab for Generalized Myasthenia Gravis
2
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
3
CTAD 2026 Preview: Clinical Trial Updates and Emerging Alzheimer Disease Research
4
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
5


